Insulin Sensitivity and the Pre-Diabetic Window Most People Miss

Key Takeaways

• Fasting glucose is a late-stage marker. Insulin resistance often develops 10–15 years before fasting glucose crosses into the pre-diabetic range.
• Fasting insulin, HOMA-IR, and 1-hour OGTT glucose detect metabolic dysfunction far earlier than HbA1c or fasting glucose alone.
• Skeletal muscle is the largest site of insulin-mediated glucose disposal; muscle mass and post-meal muscle contraction are two of the most reliable levers for improving sensitivity.
• Sleep restriction, chronic energy surplus, and prolonged sedentary behavior each independently degrade insulin sensitivity — often before body weight changes.
• The lifestyle interventions with the strongest human evidence (resistance training, aerobic base, sleep, protein-forward diet, post-meal walking) work through mechanistically different pathways and stack.

The problem with fasting glucose as a screening tool

The standard U.S. primary-care workflow — annual fasting glucose and HbA1c, flag anything above 100 mg/dL fasting or 5.7% HbA1c — misses years of metabolic decline. By the time fasting glucose is elevated, the pancreas has already been overcompensating for insulin resistance for a long time. Longitudinal work from the Whitehall II cohort (Tabák et al., 2009) showed a distinct trajectory: fasting insulin and post-load glucose rise years before fasting glucose does. Fasting glucose stays "normal" until β-cell compensation begins to fail.

That gap — sometimes a decade or more — is the window most preventive metabolic work should target. It is also the window most standard lab panels do not examine.

What insulin sensitivity actually is

Insulin sensitivity describes how efficiently a given quantity of insulin lowers blood glucose. When cells are sensitive, small amounts of insulin do a lot of work. When they are resistant, larger amounts of insulin are required to accomplish the same glucose disposal — and the pancreas responds by making more.

The compensatory hyperinsulinemia is not benign. Chronically elevated insulin drives hepatic lipogenesis, blunts fat oxidation, and contributes to the broader constellation now discussed under the umbrella of metabolic dysfunction. Hyperinsulinemia, not hyperglycemia, is the earlier chapter of the story.

The tissues that matter most

Skeletal muscle is the dominant player. This is why body composition — specifically muscle mass — is such a strong predictor of long-term metabolic resilience, largely independent of body weight.

Measuring insulin sensitivity: what to actually test

Standard fasting-glucose-only screening is inadequate for early detection. A more sensitive panel adds:

HOMA-IR above roughly 1.5–2.0 warrants attention; above 2.5 is clearly abnormal in most adults. Fasting insulin above ~10 µIU/mL is a legitimate early warning even when glucose is "normal."

The lifestyle levers with the strongest evidence

Four interventions have the largest, most consistent effect sizes on insulin sensitivity in human trials. They work through mechanistically distinct pathways, which is why they stack.

1. Skeletal muscle contraction

Acute exercise recruits GLUT4 glucose transporters to the muscle membrane through an insulin-independent pathway. That effect lasts hours after the session ends. Longer term, resistance training and aerobic base training expand the size of the glucose-disposal sink and improve mitochondrial density (Colberg et al., 2016).

Two practical patterns matter more than the specific modality:

• Total muscle mass. Larger muscle = larger glucose reservoir. This is the mechanism that makes resistance training a metabolic intervention, not just an aesthetic one.
• Post-meal contraction. Even 10–15 minutes of walking within 30–60 minutes of a meal meaningfully blunts the post-prandial glucose spike (Buffey et al., 2022).

See our companion piece on Zone 2 training for the aerobic-base mechanism.

2. Sleep

A single night of short sleep (~4 hours) measurably reduces insulin sensitivity the next morning in healthy adults (Buxton et al., 2010). Chronic sleep restriction compounds the effect. This is one of the shortest paths from lifestyle to lab value. See Sleep Architecture.

3. Energy balance and body composition

Visceral adipose tissue is metabolically active and drives systemic insulin resistance through free fatty acid flux and inflammatory cytokines. Meaningful visceral fat loss — often 5–10% of body weight in overweight individuals — reliably improves insulin sensitivity, sometimes dramatically.

4. Protein-forward, fiber-forward diet

The macronutrient pattern that most consistently supports insulin sensitivity is high in protein, high in fiber, moderate in unrefined carbohydrate, and low in ultra-processed food. The mechanism is partly compositional (fiber slows glucose absorption, protein preserves lean mass) and partly behavioral (satiety reduces total energy intake).

Pharmacology and the GLP-1 question

The rise of GLP-1 agonists has changed the conversation. These drugs improve fasting insulin, HbA1c, and body composition metrics quickly and impressively. They do not, however, replace the metabolic infrastructure — muscle mass, sleep, movement — that determines long-term resilience.

Two open questions matter:

• Do GLP-1s improve intrinsic muscle insulin sensitivity, or primarily reduce the metabolic load through weight loss and improved satiety? The evidence points more toward the latter, though the distinction gets fuzzy at the endpoint level.
• What happens after discontinuation? Weight regain and metabolic backsliding are common if the underlying behavioral inputs have not been rebuilt.

See GLP-1 Agonists and Metabolic Flexibility and Retatrutide for the pharmacology detail.

What actually moves the needle in 90 days

For someone in the pre-diabetic window — HOMA-IR 1.8–3.0, fasting insulin 10–20 µIU/mL, HbA1c 5.4–5.9% — the changes with the highest signal-to-noise ratio over a 90-day window are usually:

1. Two to three resistance-training sessions per week (add muscle mass).
2. 150+ minutes/week of Zone 2 aerobic work.
3. A short walk after the largest meal of the day.
4. 7.5+ hours of sleep on a consistent schedule.
5. A ~15–20% reduction in ultra-processed food and refined carbohydrate.

That protocol will move fasting insulin and HOMA-IR in most people. If it does not, that is itself useful information — genetic, hepatic, or endocrine factors deserve a closer look.

Current Evidence

Editorial Perspective

The dominant framing of metabolic disease as a glucose problem is a category error. It is a fuel-partitioning and signaling problem, and glucose only becomes the visible symptom after the system has been quietly compensating for years.

Three points worth holding:

First, "normal fasting glucose" is not the same as metabolically healthy. Someone with fasting glucose of 92 mg/dL, fasting insulin of 22 µIU/mL, and a HOMA-IR of 5 is not metabolically well — they are compensating well. The compensation is the disease.

Second, the intervention hierarchy has not really changed in twenty years. Sleep, muscle, movement, and diet quality remain the highest-yield inputs, and no pharmacology has yet displaced them at the mechanism level. GLP-1s are useful; they are not a replacement for the infrastructure.

Third, continuous glucose monitoring in non-diabetics is fashionable and often over-interpreted. Post-meal spikes to 140 mg/dL in a healthy adult are not a disease; they are physiology. The signal worth watching is the trajectory of fasting insulin, HOMA-IR, and 1-hour OGTT glucose over years — not individual meals.

Future Research Directions

• Standardized reference ranges for fasting insulin and HOMA-IR in preventive primary care.
• Long-term outcome data on continuous glucose monitoring in non-diabetic populations.
• Post-discontinuation metabolic trajectories after GLP-1 and dual/triple agonist therapy.
• Interaction between genetic risk (TCF7L2 and others), lifestyle, and pharmacologic response.
• Clarification of how sleep restriction and circadian disruption interact with insulin signaling at the tissue level.

FAQ

What is HOMA-IR and how do I calculate it? HOMA-IR = (fasting glucose [mg/dL] × fasting insulin [µIU/mL]) / 405. Values below ~1.5 are generally healthy; 1.5–2.5 warrant attention; above 2.5 is clearly abnormal in most adults.

Why is fasting insulin not on a standard lab panel? Historical inertia and cost. It is a cheap test and adds meaningful early-warning information; it is simply not part of most default annual physicals.

What is a 1-hour OGTT and why does it matter? An oral glucose tolerance test measures blood glucose 1 hour after a standardized glucose drink. A 1-hour value ≥155 mg/dL predicts future type 2 diabetes better than fasting glucose in multiple cohorts.

Is fasting the best way to improve insulin sensitivity? Time-restricted eating and intermittent fasting can help by reducing total energy intake and consolidating eating windows, but the effect on insulin sensitivity is largely mediated through weight loss and behavioral change. They are not uniquely powerful compared with the other levers.

How fast can insulin sensitivity change? Some markers move within days (post-exercise glucose disposal, sleep effects). HOMA-IR and fasting insulin typically show meaningful change over 8–12 weeks of consistent intervention. HbA1c lags because it reflects a 3-month average.

Do GLP-1 agonists fix insulin resistance? They improve the downstream metrics substantially, largely through weight loss, appetite reduction, and gastric emptying effects. Whether they improve intrinsic tissue sensitivity independent of those changes is less clear.

Is continuous glucose monitoring useful for a non-diabetic? It can be educational for a short period, especially for understanding individual meal responses. Interpreting isolated post-meal spikes as disease is a common mistake — the useful signal is longer-term pattern, not individual excursions.

What about supplements? Berberine, inositol, and cinnamon have small-to-modest effects in some studies. None approach the effect size of resistance training, sleep, and body composition change. Prioritize the levers with the largest effect.

References

1. Tabák AG et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373(9682):2215-2221. PubMed
2. Bergman M et al. One-hour post-load plasma glucose ≥155 mg/dL in healthy glucose tolerant adults is associated with subsequent progression to prediabetes and T2D. Acta Diabetol. 2018;55(9):935-943. PubMed
3. Colberg SR et al. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016;39(11):2065-2079. PubMed
4. Buffey AJ et al. The acute effects of interrupting prolonged sitting time on postprandial glycemia in healthy adults: a systematic review. Sports Med. 2022;52(8):1765-1787. PubMed
5. Buxton OM et al. Sleep restriction for 1 week reduces insulin sensitivity in healthy men. Diabetes. 2010;59(9):2126-2133. PubMed
6. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009;32 Suppl 2:S157-S163. PubMed

Further reading

• GLP-1 Agonists and the Question of Metabolic Flexibility
• Retatrutide (R3TA): What the Triple Agonist Research Actually Shows
• Zone 2 Training: Why the Aerobic Base Is the Real Performance Cheat Code
• Sleep Architecture: The Underrated Variable in Recovery
• Rapamycin and mTOR: The Most Studied Longevity Lever